E Bischoff

Summary

Affiliation: Bayer AG
Country: Germany

Publications

  1. ncbi Rabbits as models for impotence research
    E Bischoff
    Institute of Cardiovascular Research, Wuppertal, Germany
    Int J Impot Res 13:146-8. 2001
  2. ncbi Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events
    E Bischoff
    Bayer Pharma Research, Bayer HealthcareWuppertal, PH R EU CV ll, Wuppertal, Germany
    Int J Impot Res 16:S34-7. 2004
  3. ncbi Potency, selectivity, and consequences of nonselectivity of PDE inhibition
    E Bischoff
    Bayer Pharma Research, Bayer Healthcare Wuppertal, PH R EU CV ll, Wuppertal, Germany
    Int J Impot Res 16:S11-4. 2004
  4. ncbi A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection
    E Bischoff
    BAYER AG Pharmaceutical Business Group, Institute of Cardiovascular Research II, Wuppertal, Germany
    Int J Impot Res 13:230-5. 2001
  5. ncbi The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model
    E Bischoff
    Institute of Cardiovascular Research II, BAYER AG Pharmaceutical Business Group, Wuppertal, Germany
    J Urol 165:1316-8. 2001
  6. ncbi [PDE5 inhibitors in treatment of benign prostatic syndrome]
    P Sandner
    Bayer Health CareAG and Bayer Vital, 42096 Wuppertal
    Urologe A 46:1189-92. 2007
  7. ncbi Vardenafil reverses erectile dysfunction induced by paroxetine in rats
    J Angulo
    , , , Madrid, Spain
    Int J Impot Res 15:90-3. 2003
  8. ncbi Pro-erectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats
    F Giuliano
    Pelvipharm Laboratories, CNRS Bat 5, 1 Avenue de la Terrasse, 91140 Gif sur Yvette, France
    Eur Urol 44:731-6. 2003
  9. ncbi Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs
    J Angulo
    , Madrid, Spain
    Int J Impot Res 15:137-41. 2003
  10. ncbi BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo
    E Bischoff
    Institute of Cardiovascular Research, Bayer AG, Pharmaceutical Business Group, Wuppertal, Germany
    Urology 61:464-7. 2003

Collaborators

Detail Information

Publications11

  1. ncbi Rabbits as models for impotence research
    E Bischoff
    Institute of Cardiovascular Research, Wuppertal, Germany
    Int J Impot Res 13:146-8. 2001
    ..In conclusion, both anaesthetized rabbit model and the newly developed conscious-rabbit models are well-suited for studies in impotence research...
  2. ncbi Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events
    E Bischoff
    Bayer Pharma Research, Bayer HealthcareWuppertal, PH R EU CV ll, Wuppertal, Germany
    Int J Impot Res 16:S34-7. 2004
    ..The side effects of all selective PDE5 inhibitors commonly include vasodilation, small reductions in blood pressure, headache, and nasal congestion...
  3. ncbi Potency, selectivity, and consequences of nonselectivity of PDE inhibition
    E Bischoff
    Bayer Pharma Research, Bayer Healthcare Wuppertal, PH R EU CV ll, Wuppertal, Germany
    Int J Impot Res 16:S11-4. 2004
    ..PDE5 inhibitors may also indirectly inhibit PDE3 by increasing cyclic guanosine monophospate levels, thereby elevating heart rate and vasodilation while inhibiting platelet aggregation...
  4. ncbi A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection
    E Bischoff
    BAYER AG Pharmaceutical Business Group, Institute of Cardiovascular Research II, Wuppertal, Germany
    Int J Impot Res 13:230-5. 2001
    ..This was demonstrated using compounds that target different signaling pathways that induce smooth muscle relaxation in the penis...
  5. ncbi The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model
    E Bischoff
    Institute of Cardiovascular Research II, BAYER AG Pharmaceutical Business Group, Wuppertal, Germany
    J Urol 165:1316-8. 2001
    ..The clinical development of this product for erectile dysfunction is proceeding...
  6. ncbi [PDE5 inhibitors in treatment of benign prostatic syndrome]
    P Sandner
    Bayer Health CareAG and Bayer Vital, 42096 Wuppertal
    Urologe A 46:1189-92. 2007
  7. ncbi Vardenafil reverses erectile dysfunction induced by paroxetine in rats
    J Angulo
    , , , Madrid, Spain
    Int J Impot Res 15:90-3. 2003
    ....
  8. ncbi Pro-erectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats
    F Giuliano
    Pelvipharm Laboratories, CNRS Bat 5, 1 Avenue de la Terrasse, 91140 Gif sur Yvette, France
    Eur Urol 44:731-6. 2003
    ..To assess pro-erectile responses to vardenafil, a new selective PDE5 inhibitor, in vitro in isolated rabbit corpora cavernosa, and in vivo in anaesthetized rats...
  9. ncbi Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs
    J Angulo
    , Madrid, Spain
    Int J Impot Res 15:137-41. 2003
    ....
  10. ncbi BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo
    E Bischoff
    Institute of Cardiovascular Research, Bayer AG, Pharmaceutical Business Group, Wuppertal, Germany
    Urology 61:464-7. 2003
    ..Because the effect is increased by SNP, it can be expected that BAY 41-2272 would have enhanced activity during sexual arousal, when NO is produced endogenously...
  11. ncbi PDE5 inhibitors beyond erectile dysfunction
    P Sandner
    Product Related Research, Bayer HealthCare, Wuppertal, Germany
    Int J Impot Res 19:533-43. 2007
    ..The aim of this review is to summarize existing preclinical and clinical knowledge and critically discuss the evidence to support potential future indications for PDE5 inhibitors...